bococizumab
Jump to navigation
Jump to search
Introduction
Not yet FDA-approved.
Indications
- high-risk cardiovascular disease*
* no benefit in lower-risk patients
Dosage
Adverse effects
- antidrug antibodies markedly diminish magnitude & durability of LDL cholesterol reduction[1]
- drug adverse effects of anti-hyperlipidemic agents
- drug adverse effects of PCSK9 inhibitor(s)
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
- PCSK9 inhibitor, fully humanized monoclonal antibody
More general terms
References
- ↑ 1.0 1.1 Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med 2017 Mar 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28304227
- ↑ 2.0 2.1 Ridker PM, Revkin J, Amarenco P Cardiovascular Efficacy and Safety of Bococizumab in High- Risk Patients. N Engl J Med. 2017 Mar 17 -> 376:1527-1539. April 20, 2017 http://www.nejm.org/doi/full/10.1056/NEJMoa1701488 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28304242 Free full text